Clinical Trials Directory

Trials / Conditions / Refractory Malignant Neoplasm

Refractory Malignant Neoplasm

14 registered clinical trials studyying Refractory Malignant Neoplasm.

StatusTrialSponsorPhase
Active Not RecruitingCombination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advance
NCT03203525
M.D. Anderson Cancer CenterPhase 1
CompletedHypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
NCT04409314
University of California, San Francisco—
Active Not RecruitingFinancial Distress in Advanced Cancer Patients
NCT04053517
M.D. Anderson Cancer Center—
TerminatedDNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating P
NCT03439085
M.D. Anderson Cancer CenterPhase 2
CompletedCobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
NCT03108131
M.D. Anderson Cancer CenterPhase 2
CompletedTesting the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication
NCT02595866
National Cancer Institute (NCI)Phase 1
Active Not RecruitingPhysical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
NCT02491632
M.D. Anderson Cancer CenterPhase 2 / Phase 3
CompletedPCRC-Supported Legacy Intervention in Pediatric Palliative Care
NCT04059393
Vanderbilt-Ingram Cancer CenterN/A
CompletedNavitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
NCT02143401
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTalazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations i
NCT02286687
M.D. Anderson Cancer CenterPhase 2
CompletedEverolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
NCT01624766
M.D. Anderson Cancer CenterPhase 1
CompletedVandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
NCT01582191
M.D. Anderson Cancer CenterPhase 1
Active Not RecruitingBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With
NCT01552434
M.D. Anderson Cancer CenterPhase 1
CompletedVemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mu
NCT01531361
M.D. Anderson Cancer CenterPhase 1